Xenon Shares Surge on Promising Epilepsy Treatment Results by B.C. Developer
Xenon Pharmaceuticals Inc. has witnessed a significant surge in its stock following promising results from a late-stage clinical trial for its epilepsy treatment. Based in Burnaby, British Columbia, the company revealed it will seek approval from the U.S. Food and Drug Administration (FDA) to market the drug, azetukalner, this year.
Xenon’s Epilepsy Treatment Breakthrough
After announcing the trial results, Xenon’s stock price rose by nearly 49.6%, closing at US$62.76 per share on the Nasdaq. The company’s market capitalization has now reached US$5 billion, confirming its status as Canada’s most valuable drug developer. This marks a crucial moment for individuals with epilepsy, as noted by CEO Ian Mortimer.
Trial Results and Patient Impact
- The trial included 380 participants.
- Patients taking a 25 mg daily dose of azetukalner experienced a 53.2% median reduction in seizures.
- This result surpassed the 34.6 percentage points better outcomes for placebo recipients.
- A secondary group taking a 15 mg dose seen a 34.5% reduction.
These findings exceed earlier results from a 2021 trial, where a 52.8% reduction was noted over eight weeks. Analysts praised the data as the strongest from a phase III trial for focal onset seizures, laying the groundwork for commercial success.
Market Potential and Future Prospects
Experts are optimistic about azetukalner’s market potential. Jefferies analyst Andrew Tsai projected peak annual sales could reach US$2 billion, reflecting the drug’s strong attributes. Unlike many existing treatments requiring gradual dose increases, azetukalner can be taken nightly to minimize side effects.
Continuing Research and Financial Strategy
Xenon is exploring additional studies to assess azetukalner’s effectiveness against mood disorders and pain. The drug has already shown promise in treating patients who have been resistant to multiple anti-seizure medications.
Additionally, Xenon announced a plan for a public offering to raise US$500 million for its commercial launch. Since its inception in 1996, Algernon has raised a total of US$1.4 billion to date.
Background and Acquisition Details
Xenon was originally focused on gene discovery but shifted towards pain management. The company went public in 2014, but faced challenges that affected its stock. In 2017, it acquired rights to azetukalner from Valeant Pharmaceuticals, which had encountered issues with a similar drug.
The total cost to acquire the rights to azetukalner is expected to be approximately US$15 million if it secures market approval. This amount highlights the financial planning involved in bringing this promising treatment to patients.
As Xenon prepares for potential FDA approval and the next stages of its journey, the company aims to make a significant impact in the treatment landscape for epilepsy, offering hope to countless individuals affected by the condition.
